These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 6133301)

  • 1. Sedative effects and prolactin response to single oral doses of melperone.
    Molander L; Borgström L
    Psychopharmacology (Berl); 1983; 79(2-3):142-7. PubMed ID: 6133301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between plasma concentration and arousal in normal subjects after single oral and parenteral doses of melperone, a butyrophenone neuroleptic.
    Molander L; Borgström L
    Psychopharmacology (Berl); 1983; 79(2-3):111-4. PubMed ID: 6133299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics.
    Bobo WV; Jayathilake K; Lee MA; Meltzer HY
    Hum Psychopharmacol; 2009 Jul; 24(5):415-22. PubMed ID: 19551763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of melperone, two of its metabolites and thiothixene on central monoamine metabolism and prolactin levels in rodents.
    Wiesel FA; Bjerkenstedt L; Skett P
    Acta Pharmacol Toxicol (Copenh); 1978 Aug; 43(2):129-36. PubMed ID: 696342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia.
    Sumiyoshi T; Jayathilake K; Meltzer HY
    Schizophr Res; 2003 Jan; 59(1):7-16. PubMed ID: 12413636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs.
    Meltzer HY; Koenig JI; Nash JF; Gudelsky GA
    Acta Psychiatr Scand Suppl; 1989; 352():24-9. PubMed ID: 2573238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological data of the atypical neuroleptic compound melperone (Buronil).
    Christensson EG
    Acta Psychiatr Scand Suppl; 1989; 352():7-15. PubMed ID: 2573242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Electrophysiological effects of melperone in the dog heart in situ - a new antiarrhythmic drug.
    Refsum H; Amlie JP; Platou ES; Owren T; Landmark K
    Cardiovasc Res; 1981 Mar; 15(3):131-6. PubMed ID: 6114796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mode of antiarrhythmic action of melperone.
    Platou ES; Refsum H; Myhre ES; Amlie JP; Landmark K
    Acta Pharmacol Toxicol (Copenh); 1982 Feb; 50(2):108-12. PubMed ID: 6122332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels and cardiac electrophysiological effects of melperone in the dog.
    Platou ES; Refsum H; Amlie JP; Landmark K
    Eur J Pharmacol; 1982 Aug; 82(1-2):1-7. PubMed ID: 7128676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of beta-adrenergic and cholinergic blockade on the electrophysiological effects of melperone in the dog heart in situ.
    Platou ES; Refsum H; Amlie JP; Landmark K
    Cardiovasc Res; 1981 Mar; 15(3):137-43. PubMed ID: 6114797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics.
    Bobo WV; Jayathilake K; Lee MA; Meltzer HY
    Psychiatry Res; 2010 Apr; 176(2-3):114-9. PubMed ID: 20199813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative analysis of melperone in human plasma by gas chromatography--mass spectrometry--selected ion monitoring.
    Chan KY; Okerholm RA
    J Chromatogr; 1983 May; 274():121-7. PubMed ID: 6135699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey.
    Hefner G; Unterecker S; Shams ME; Wolf M; Falter T; Haen E; Hiemke C
    J Neural Transm (Vienna); 2015 Nov; 122(11):1609-17. PubMed ID: 25940834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open study of tolerability and pharmacokinetics of raclopride extended release capsules in psychiatric patients: a Canadian study.
    Gendron A; Sirois G; Nair NP; Bloom D; Movin-Osswald G; Uppfeldt G
    J Psychiatry Neurosci; 1995 Jul; 20(4):287-96. PubMed ID: 7647082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of single oral doses of various neuroleptic drugs on salivary secretion rate, pH, and buffer capacity in healthy subjects.
    Molander L; Birkhed D
    Psychopharmacology (Berl); 1981; 75(2):114-8. PubMed ID: 6119724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective alpha-adrenoceptor blocking action of melperone.
    Jiang ZW; Liu TP
    Zhongguo Yao Li Xue Bao; 1988 Jul; 9(4):316-20. PubMed ID: 2904206
    [No Abstract]   [Full Text] [Related]  

  • 18. Correlation between melperone plasma concentrations and changes in the effective refractory period of the right atrium and ventricle of the dog.
    Landmark K; Amlie JP; Refsum H; Platou ES
    Acta Pharmacol Toxicol (Copenh); 1979 Aug; 45(2):166-8. PubMed ID: 40392
    [No Abstract]   [Full Text] [Related]  

  • 19. Electrophysiological effects of melperone on isolated rabbit heart muscles.
    Ikeguchi S; Hashimoto S; Horie M; Kadoya M; Konishi T; Kawai C
    Br J Pharmacol; 1988 Aug; 94(4):1063-8. PubMed ID: 3207973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of parenteral and oral melperone in man.
    Borgström L; Larsson H; Molander L
    Eur J Clin Pharmacol; 1982; 23(2):173-6. PubMed ID: 7140807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.